| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.2 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.07 | 0.2 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |